Jump to content

Cyclooxygenase-2 inhibitor

From Wikipedia, the free encyclopedia
(Redirected from COX-2 inhibitor)

Cyclooxygenase-2 inhibitors (COX-2 inhibitors), also known as coxibs, are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly target cyclooxygenase-2 (COX-2), an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class.[1]

After several COX-2–inhibiting drugs were approved for marketing, data from clinical trials revealed that COX-2 inhibitors caused a significant increase in heart attacks and strokes, with some drugs in the class having worse risks than others. Rofecoxib (sold under the brand name Vioxx) was taken off the market in 2004 because of these concerns, while celecoxib (sold under the brand name Celebrex) and traditional NSAIDs received boxed warnings on their labels. Many COX-2–specific inhibitors have been removed from the US market. As of December 2011, only Celebrex (celecoxib) is still available for purchase in the United States. In the European Union, celecoxib, parecoxib, and etoricoxib have been approved for use by the European Medicines Agency.[2]

Paracetamol (acetaminophen) inhibits COX-2 almost exclusively within the brain and only minimally in the rest of the body, although it is not considered an NSAID, since it has only minor anti-inflammatory activity.[3][4]

Medical uses

[edit]

Some COX-2 inhibitors are used in a single dose to treat pain after surgery.[5][6] In this role etoricoxib appears as good as, if not better than, other pain medications, and celecoxib appears to be about as useful as ibuprofen.[7][8]

NSAIDs are often used in treatment of acute gout attacks. COX-2 inhibitors appear to work as well as nonselective NSAIDs, such as aspirin.[9] They have not been compared to other treatment options such as colchicine or glucocorticoids.[9][10]

Cancer

[edit]

COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. Overexpression of COX-2 produces excess prostaglandins, which have been shown to increase the possibility of colorectal cancer.[11] COX inhibitors have been shown to reduce the occurrence of cancers and precancerous growths. The National Cancer Institute has done some studies on COX-2 and cancer.[12] COX-2 can act as an anti-tumor enzyme, but only in specific cases.[13] The FDA has approved Celebrex for treatment of familial adenomatous polyposis (FAP).[14] COX-2 inhibitors are currently being studied in breast cancer[15] and appear to be beneficial.[16]

Neuropsychiatric disorders

[edit]

COX-2 inhibitors have been found to be effective in suppressing inflammatory neurodegenerative pathways, with beneficial results in animal studies for major depressive disorder, as well as schizophrenia, bipolar disorder, and obsessive-compulsive disorder.[17] These need to be confirmed in human clinical trials.[18] Current studies support an association of disorders such as these with chronic inflammation, which appears to decrease with the use of COX-2 inhibitors.[17]

Other targets

[edit]

The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib. However, with regard to this drug's promise for the therapy of advanced cancers, it is unclear whether the inhibition of COX-2 plays a dominant role, and this has become a controversial and intensely researched issue. In recent years, several additional intracellular components (besides COX-2) were discovered that appear to be important for mediating the anticancer effects of celecoxib in the absence of COX-2.[19] Moreover, a recent study with various malignant tumor cells showed that celecoxib could inhibit the growth of these cells, even though some of these cancer cells didn't even contain COX-2.[20]

Additional support for the idea that other targets besides COX-2 are important for celecoxib's anticancer effects has come from studies with chemically modified versions of celecoxib. Several dozen analogs of celecoxib were generated with small alterations in their chemical structures.[21] Some of these analogs retained COX-2 inhibitory activity, whereas many others didn't. However, when the ability of all these compounds to kill tumor cells in cell culture was investigated, it turned out that the antitumor potency did not at all depend on whether or not the respective compound could inhibit COX-2, showing that inhibition of COX-2 was not required for the anticancer effects.[21][22] One of these compounds, 2,5-dimethyl-celecoxib, which entirely lacks the ability to inhibit COX-2, actually turned out to display stronger anticancer activity than celecoxib itself[23] and this anticancer effect could also be verified in highly drug-resistant tumor cells[24] and in various animal tumor models.[25][26]

Adverse effects

[edit]

Analysis of clinical trial data revealed that there was a significant increase in the rate of vascular events like myocardial infarction or stroke with COX-2 inhibitors compared with placebo.[27][28] These results led Merck to voluntarily withdraw (rofecoxib) from the market in September 2004 and to regulatory authorities imposing a boxed warning on the label of celecoxib.[27] Traditional NSAIDs were also found to have cardiovascular risks, leading to similar boxed warnings.[27]

The cause of the cardiovascular problems became, and remains, a subject of intensive research.[29] As of 2012 results have been converging on the hypothesis that the adverse cardiovascular effects are most likely due to inhibition of COX-2 in blood vessels, which leads to a decrease in the production of prostacyclin in them. Prostacyclin usually prevents platelet aggregation and vasoconstriction, so its inhibition can lead to excess clot formation and higher blood pressure.[29]

Research

[edit]

Research history

[edit]
Further information: Discovery and development of cyclooxygenase 2 inhibitors

The COX-2 enzyme was discovered in 1988 by Daniel Simmons, a Brigham Young University researcher.[30] The mouse COX-2 gene was cloned by UCLA scientist Harvey Herschman, a finding published in 1991.[31]

The basic research leading to the discovery of COX-2 inhibitors has been the subject of at least two lawsuits. Brigham Young University has sued Pfizer, alleging breach of contract from relations BYU had with the company at the time of Simmons's work.[32][33] A settlement was reached in April 2012 in which Pfizer agreed to pay $450 million.[34][35] The other litigation is based on United States Pat. No. 6,048,850[36] owned by University of Rochester, which claimed a method to treat pain without causing gastro-intestinal distress by selectively inhibiting COX-2. When the patent issued, the university sued Searle (later Pfizer) in a case called, University of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004). The court ruled in favor of Searle in 2004, holding in essence that the university had claimed a method requiring, yet provided no written description of, a compound that could inhibit COX-2 and therefore the patent was invalid.[37][38]

In the course of the search for a specific inhibitor of the negative effects of prostaglandins that spared the positive effects, it was discovered that prostaglandins could indeed be separated into two general classes that could loosely be regarded as "good prostaglandins" and "bad prostaglandins", according to the structure of a particular enzyme involved in their biosynthesis, cyclooxygenase.

Prostaglandins whose synthesis involves the cyclooxygenase-I enzyme, or COX-1, are responsible for maintenance and protection of the gastrointestinal tract, while prostaglandins whose synthesis involves the cyclooxygenase-II enzyme, or COX-2, are responsible for inflammation and pain.

The existing nonsteroidal anti-inflammatory drugs (NSAIDs) differ in their relative specificities for COX-2 and COX-1; while aspirin and ibuprofen inhibit COX-2 and COX-1 enzymes, other NSAIDs appear to have partial COX-2 specificity, particularly meloxicam (Mobic).[39] Aspirin is ≈170-fold more potent in inhibiting COX-1 than COX-2.[40] Studies of meloxicam 7.5 mg per day for 23 days find a level of gastric injury similar to that of a placebo, and for meloxicam 15 mg per day a level of injury lower than that of other NSAIDs; however, in clinical practice meloxicam can still cause some ulcer complications.

Valdecoxib and rofecoxib were about 300 times more potent at inhibiting COX-2 than COX-1, but too toxic for the heart, suggesting the possibility of relief from pain and inflammation without gastrointestinal irritation, and promising to be a boon for those who had previously experienced adverse effects or had comorbidities that could lead to such complications. Celecoxib is approximately 30 times more potent at inhibiting COX-2 than COX-1, with etoricoxib being 106 times more potent.

Research fraud

[edit]

Between 1996 and 2009, Scott Reuben purportedly conducted clinical research on the use of COX-2 inhibitors, often in combination with gabapentin or pregabalin, for the prevention and treatment of postoperative pain, research which was found in 2009 to have been faked. Reuben pleaded guilty, paid fines, and served six months in jail, and lost his medical license.[41] A 2009 review of meta-articles used in evidence-based medicine found that while some reviews were no longer valid when the Reuben studies were removed, the conclusions in the majority of them remained unchanged.[42] The review found that the key Reuben claims that needed to be re-examined were "the absence of detrimental effects of coxibs on bone healing after spine surgery, the beneficial long-term outcome after preemptive administration of coxibs including an allegedly decreased incidence of chronic pain after surgery, and the analgesic efficacy of ketorolac or clonidine when added to local anesthetics for intravenous regional anesthesia."[42][43]

Early COX-2-inhibiting drugs

[edit]

Celebrex (and other brand names for celecoxib) was introduced in 1999 and rapidly became the most frequently prescribed new drug in the United States. By October 2000, its US sales exceeded 100 million prescriptions per year for $3 billion, and was still rising. Sales of Celebrex alone reached $3.1 billion in 2001. A Spanish study found that between January 2000 and June 2001, 7% of NSAID prescriptions and 29% of NSAID expenditures were for COX-2 inhibitors. Over the period of the study, COX-2 inhibitors rose from 10.03% of total NSAIDs prescribed by specialty physicians to 29.79%, and from 1.52% to 10.78% of NSAIDs prescribed by primary care physicians (98.23% of NSAIDs and 94.61% of COX-2 inhibitors were prescribed by primary care physicians). For specialty physicians, rofecoxib and celecoxib were third and fifth most frequently prescribed NSAIDs but first and second in cost, respectively; for primary-care physicians they were ninth and twelfth most frequently prescribed NSAIDs and first and fourth in cost.

Sales and marketing efforts were supported by two large trials, the Celecoxib Long-term Arthritis Safety Study[44] (CLASS) in JAMA, and the Vioxx Gastrointestinal Outcomes Research (VIGOR).[45] The VIGOR trial was later proven to have been based on faulty data, and Vioxx was eventually withdrawn from the market.[46]

VIGOR study and publishing controversy

[edit]

The VIGOR (Vioxx Gastrointestinal Outcomes Research) trial, "which was the making of Merck's drug rofecoxib (Vioxx),"[46] was at the center of a dispute about the ethics of medical journals. In the VIGOR trial, over 8,000 patients were randomized to receive either naproxen or rofecoxib (Vioxx). Both studies concluded that COX-2 specific NSAIDs were associated with significantly fewer adverse gastrointestinal effects. In the CLASS trial which compared Celebrex 800 mg/day to ibuprofen 2400 mg/day and diclofenac 150 mg/day for osteoarthritis or rheumatoid arthritis for six months, Celebrex was associated with significantly fewer upper gastrointestinal complications (0.44% vs. 1.27%, p = 0.04), with no significant difference in incidence of cardiovascular events in patients not taking aspirin for cardiovascular prophylaxis.

The VIGOR trial results were published in 2000 in the New England Journal of Medicine[47] Bombardier and his research team claimed that there was "an increase in myocardial infarction in the patients given rofecoxib (0.4%) compared with those given naproxen (0.1%)" and "patients given naproxen experienced 121 side effects compared with 56 in the patients taking rofecoxib," a "marvellous result for Merck" which "contributed to huge sales of rofecoxib."[46] Merck's scientists incorrectly interpreted the finding as a protective effect of naproxen, telling the FDA that the difference in heart attacks "is primarily due to" this protective effect.[48] In September 2001, the United States Food and Drug Administration (FDA) sent a warning letter to the CEO of Merck, stating, "Your promotional campaign discounts the fact that in the VIGOR study, patients on Vioxx were observed to have a four to five fold increase in myocardial infarctions (MIs) compared to patients on the comparator nonsteroidal anti-inflammatory drug (NSAID), Naprosyn (naproxen)."[49] This led to the introduction, in April 2002, of warnings on Vioxx labeling concerning the increased risk of cardiovascular events (heart attack and stroke). By 2005 The New England Journal of Medicine published an editorial accusing the Bombardier et al. of deliberately withholding data.[50]

Claire Bombardier, a University of Toronto rheumatologist, had claimed that the VIGOR trial showed that Vioxx 50 mg/day had benefits over naproxen for rheumatoid arthritis, specifically that Vioxx reduced the risk of symptomatic ulcers and clinical upper gastrointestinal events (perforations, obstructions and bleeding) by 54%, to 1.4% from 3%, the risk of complicated upper gastrointestinal events (complicated perforations, obstructions and bleeding in the upper gastrointestinal tract) by 57%, and the risk of bleeding from anywhere in the gastrointestinal tract by 62%. An enormous marketing effort capitalized on these publications; Vioxx was the most heavily advertised prescription drug in 2000, and Celebrex the seventh, according to IMS Health.

Neuroblastomas

[edit]

Small tumors of the sympathetic nervous system (neuroblastoma) appear to have abnormal levels of COX-2 expressed.[51] These studies report that overexpression of the COX-2 enzyme has an adverse effect on the tumor suppressor, p53. p53 is an apoptosis transcription factor normally found in the cytosol. When cellular DNA is damaged beyond repair, p53 is transported to the nucleus where it promotes p53 mediated apoptosis.[52] Two of the metabolites of COX-2, prostaglandin A2 (PGA2) and A1 (PGA1), when present in high quantities, bind to p53 in the cytosol and inhibit its ability to cross into the nucleus. This essentially sequesters p53 in the cytosol and prevents apoptosis.[52] Coxibs such as Celebrex (celecoxib), by selectively inhibiting the overexpressed COX-2, allow p53 to work properly. Functional p53 allows DNA damaged neuroblastoma cells to commit suicide through apoptosis, halting tumor growth.

COX-2 up-regulation has also been linked to the phosphorylation and activation of the E3 ubiquitin ligase HDM2, a protein that mediates p53 ligation and tagged destruction, through ubiquitination.[52] The mechanism for this neuroblastoma HDM2 hyperactivity is unknown. Studies have shown that COX-2 inhibitors block the phosphorylation of HDM2 preventing its activation. In vitro, the use of COX-2 inhibitors lowers the level of active HDM2 found in neuroblastoma cells. The exact process of how COX-2 inhibitors block HDM2 phosphorylation is unknown, but this mediated reduction in active HDM2 concentration level restores the cellular p53 levels. After treatment with a COX-2 inhibitor, the restored p53 function allows DNA damaged neuroblastoma cells to commit suicide through apoptosis reducing the size of growth of the tumor.[52]

References

[edit]
  1. ^ Lipfert P, Seitz R, Arndt JO (February 1987). "Studies of local anesthetic action on natural spike activity in the aortic nerve of cats". Anesthesiology. 66 (2). Ovid Technologies (Wolters Kluwer Health): 210–213. doi:10.1097/00000542-198702000-00016. PMID 3813081. Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs).
  2. ^ "Public data from Article 57 database". European Medicines Agency. 17 September 2018. Archived from the original on 2018-10-02. Retrieved 25 June 2021.
  3. ^ Hinz B, Cheremina O, Brune K (February 2008). "Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man". FASEB Journal. 22 (2): 383–90. doi:10.1096/fj.07-8506com. PMID 17884974. S2CID 9633350.
  4. ^ Page CP, Curtis MJ, Sutter M, Walker M, Hoffman B (1998). Farmacología integrada (in Spanish). Elsevier España. ISBN 84-8174-340-2 – via Google Books.
  5. ^ Tirunagari SK, Derry S, Moore RA, McQuay HJ (July 2009). "Single dose oral etodolac for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 2019 (3): CD007357. doi:10.1002/14651858.CD007357.pub2. PMC 4164827. PMID 19588426.
  6. ^ Bulley S, Derry S, Moore RA, McQuay HJ (October 2009). "Single dose oral rofecoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 2009 (4): CD004604. doi:10.1002/14651858.CD004604.pub3. PMC 4171390. PMID 19821329.
  7. ^ Clarke R, Derry S, Moore RA (May 2014). "Single dose oral etoricoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 2019 (5): CD004309. doi:10.1002/14651858.CD004309.pub4. PMC 6485336. PMID 24809657.
  8. ^ Derry S, Moore RA (October 2013). "Single dose oral celecoxib for acute postoperative pain in adults". The Cochrane Database of Systematic Reviews. 10 (10): CD004233. doi:10.1002/14651858.CD004233.pub4. PMC 4161494. PMID 24150982.
  9. ^ a b van Durme CM, Wechalekar MD, Landewé RB, Pardo Pardo J, Cyril S, van der Heijde D, Buchbinder R (December 2021). "Non-steroidal anti-inflammatory drugs for acute gout". The Cochrane Database of Systematic Reviews. 2021 (12): CD010120. doi:10.1002/14651858.CD010120.pub3. PMC 8656463. PMID 34882311.
  10. ^ van Durme CM, Wechalekar MD, Landewé RB (June 2015). "Nonsteroidal anti-inflammatory drugs for treatment of acute gout". JAMA. 313 (22): 2276–2277. doi:10.1001/jama.2015.1881. PMID 26057289.
  11. ^ Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (March 2009). "The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment". Carcinogenesis. 30 (3): 377–386. doi:10.1093/carcin/bgp014. PMID 19136477.
  12. ^ "COX-2 Inhibitors and Cancer". Fact Sheet. United States National Cancer Institute. Archived from the original on May 9, 2008.
  13. ^ Desai SJ, Prickril B, Rasooly A (April 2018). "Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer". Nutrition and Cancer. 70 (3): 350–375. doi:10.1080/01635581.2018.1446091. PMC 6309701. PMID 29578814.
  14. ^ "FDA Approves Celebrex for New Indication". U.S. Food and Drug Administration. 23 December 1999. Archived from the original on May 10, 2008. Retrieved May 8, 2008.
  15. ^ Chow LW, Loo WT, Toi M (October 2005). "Current directions for COX-2 inhibition in breast cancer". Biomedicine & Pharmacotherapy. 59 (Suppl 2): S281 – S284. doi:10.1016/S0753-3322(05)80046-0. PMID 16507393.
  16. ^ Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K (December 2007). "COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia". British Journal of Cancer. 97 (11): 1523–1531. doi:10.1038/sj.bjc.6604057. PMC 2360252. PMID 17971769.
  17. ^ a b Sethi R, Gómez-Coronado N, Walker AJ, Robertson OD, Agustini B, Berk M, Dodd S (4 September 2019). "Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders". Frontiers in Psychiatry. 10: 605. doi:10.3389/fpsyt.2019.00605. PMC 6738329. PMID 31551825.
  18. ^ Müller N (January 2010). "COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence". Current Opinion in Investigational Drugs. 11 (1): 31–42. PMID 20047157.
  19. ^ Schönthal AH (December 2007). "Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy". British Journal of Cancer. 97 (11): 1465–1468. doi:10.1038/sj.bjc.6604049. PMC 2360267. PMID 17955049.
  20. ^ Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (May 2008). "COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro". Molecular Cancer. 7: 38. doi:10.1186/1476-4598-7-38. PMC 2396175. PMID 18485224.
  21. ^ a b Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (December 2002). "Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents". Journal of the National Cancer Institute. 94 (23): 1745–1757. doi:10.1093/jnci/94.23.1745. PMID 12464646.
  22. ^ Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (February 2008). "Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs". Expert Opinion on Investigational Drugs. 17 (2): 197–208. doi:10.1517/13543784.17.2.197. PMID 18230053. S2CID 21093404.
  23. ^ Schönthal AH (April 2006). "Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy". Neurosurgical Focus. 20 (4): E21. doi:10.3171/foc.2006.20.4.14. PMID 16709027.
  24. ^ Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, et al. (December 2005). "Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib". Blood. 106 (13): 4330–4338. doi:10.1182/blood-2005-07-2819. PMID 16123214.
  25. ^ Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, et al. (April 2007). "Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib". Molecular Cancer Therapeutics. 6 (4): 1262–1275. doi:10.1158/1535-7163.MCT-06-0629. PMID 17431104. S2CID 34283027.
  26. ^ Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (May 2005). "Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo". Cancer Biology & Therapy. 4 (5): 571–582. doi:10.4161/cbt.4.5.1699. PMID 15846081. S2CID 21046732.
  27. ^ a b c Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (March 2007). "Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association". Circulation. 115 (12): 1634–1642. doi:10.1161/CIRCULATIONAHA.106.181424. PMID 17325246.
  28. ^ Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (June 2006). "Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials". BMJ. 332 (7553): 1302–1308. doi:10.1136/bmj.332.7553.1302. PMC 1473048. PMID 16740558.
  29. ^ a b Cannon CP, Cannon PJ (June 2012). "Physiology. COX-2 inhibitors and cardiovascular risk". Science. 336 (6087): 1386–1387. Bibcode:2012Sci...336.1386C. doi:10.1126/science.1224398. PMID 22700906. S2CID 36654810.
  30. ^ Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (April 1991). "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing". Proceedings of the National Academy of Sciences of the United States of America. 88 (7): 2692–2696. Bibcode:1991PNAS...88.2692X. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272.
  31. ^ Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (July 1991). "TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue". The Journal of Biological Chemistry. 266 (20): 12866–12872. doi:10.1016/S0021-9258(18)98774-0. PMID 1712772.
  32. ^ Yajnik J (2006-10-27). "University sues Pfizer over COX-2 research". The Scientist. Archived from the original on 2009-02-03. Retrieved 2010-11-11.
  33. ^ Harvey T (2010-09-21). "BYU spices up Celebrex lawsuit against Pfizer". The Salt Lake Tribune. Retrieved 2011-02-28.
  34. ^ Harvey T (May 1, 2012). "Pfizer, BYU settle Celebrex lawsuit for $450M". The Salt Lake Tribune.
  35. ^ "Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex". The New York Times. Associated Press. 1 May 2012.
  36. ^ US 6048850, Young DA, O'Banion MK, Winn VD, "Method of inhibiting prostaglandin synthesis in a human host", issued 11 April 2000, assigned to University of Rochester. 
  37. ^ Kadle R, ed. (2010). "Reach-Through Claims Declared Invalid". Publications: Hodgson Russ LLP. Archived from the original on 1 August 2010. Retrieved 2015-05-23.
  38. ^ University Of Rochester, Plaintiff-Appellant, V. G.D. Searle & Co., Inc., Monsanto Company, Pharmacia Corporation, and Pfizer Inc., Defendants-Appellees., 358 F.3d 916; 2004 U.S. App. LEXIS 2458; 69 U.S.P.Q.2D (BNA) 1886 917 (United States Court of Appeals for the Federal Circuit 13 February 2004) ("The University of Rochester ("Rochester") appeals from the decision of the United States District Court for the Western District of New York granting summary judgment that United States Patent 6,048,850 is invalid. Univ. of Rochester v. G.D. Searle & Co., 249 F. Supp. 2d 216 (W.D.N.Y. 2003). Because we conclude that the court did not err in holding the '850 patent invalid for failing to comply with the written description requirement of 35 U.S.C. § 112, P 1, and in granting summary judgment on that ground, we affirm."), archived from the original on 21 July 2013.
  39. ^ Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K (2022). "Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors". RSC Medicinal Chemistry. 13 (5): 471–496. doi:10.1039/D1MD00280E. PMC 9132194. PMID 35685617.
  40. ^ Awtry EH, Loscalzo J (March 2000). "Aspirin". Circulation. 101 (10): 1206–1218. doi:10.1161/01.cir.101.10.1206. PMID 10715270.
  41. ^ Borrell B (10 March 2009). "A Medical Madoff: Anesthesiologist Faked Data in 21 Studies". Scientific American.
  42. ^ a b Marret E, Elia N, Dahl JB, McQuay HJ, Møiniche S, Moore RA, et al. (December 2009). "Susceptibility to fraud in systematic reviews: lessons from the Reuben case". Anesthesiology. 111 (6): 1279–1289. doi:10.1097/ALN.0b013e3181c14c3d. PMID 19934873.
  43. ^ White PF, Rosow CE, Shafer SL (March 2011). "The Scott Reuben saga: one last retraction". Anesthesia and Analgesia. 112 (3): 512–515. doi:10.1213/ANE.0b013e318209736f. PMID 21350225. S2CID 2857883.
  44. ^ Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. (September 2000). "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study". JAMA. 284 (10): 1247–1255. doi:10.1001/jama.284.10.1247. PMID 10979111.
  45. ^ Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. (November 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". The New England Journal of Medicine. 343 (21): 1520–8, 2 p following 1528. doi:10.1056/NEJM200011233432103. PMID 11087881.
  46. ^ a b c Smith R (August 2006). "Lapses at the new England journal of medicine". Journal of the Royal Society of Medicine. 99 (8): 380–382. doi:10.1177/014107680609900802. PMC 1533509. PMID 16893926.
  47. ^ Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. (November 2000). "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group". The New England Journal of Medicine. 343 (21). New England Journal of Medicine: 1520–8, 2 p following 1528. doi:10.1056/NEJM200011233432103. PMID 11087881.
  48. ^ "NAME OF DRUG: Rofecoxib (MK-0966) : Memorandum" (PDF). Fda.gov. Retrieved 4 January 2015.
  49. ^ Abrams TW (17 September 2001). "Warning Letter" (PDF). Division of Drug Marketing, Advertising, and Communications. Letter to Raymond V Gilmartin (Merck & Co., Inc). U.S. Food and Drug Administration. Archived from the original (PDF) on 6 January 2012. Retrieved 4 January 2015.
  50. ^ Curfman GD, Morrissey S, Drazen JM (December 2005). "Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8". The New England Journal of Medicine. 353 (26): 2813–2814. doi:10.1056/NEJMe058314. PMID 16339408. S2CID 10745161.
  51. ^ Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, et al. (October 2004). "Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo". Cancer Research. 64 (20): 7210–7215. doi:10.1158/0008-5472.CAN-04-1795. PMID 15492235. S2CID 10865602.
  52. ^ a b c d Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, Kaplan DR, Irwin MS (March 2007). "Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma". Oncogene. 26 (13): 1920–1931. doi:10.1038/sj.onc.1209981. PMID 16983334. S2CID 21996428.

Further reading

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cyclooxygenase-2_inhibitor&oldid=1217198609"